Divalproex Sodium

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

81 API Suppliers, 36 USDMF, 10 CEP/COS, 3 JDMF, 14 EU WC, 9 KDMF, 16 NDC API, 39 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

44 Drugs in Development

44 Drugs in Development

FINISHED DOSAGE FORMULATIONS

311 FDF Dossiers, 111 FDA Orange Book, 101 Europe, 17 Canada, 26 Australia, 19 South Africa, 37 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

CAPSULE;ORAL - 250MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, SYRUP;ORAL - 250MG/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET, DELAYED RELEASE;ORAL - EQ 125MG VALPROIC ACID, TABLET, DELAYED RELEASE;ORAL - EQ 250MG VALPROIC ACID, TABLET, DELAYED RELEASE;ORAL - EQ 500MG VALPROIC ACID, CAPSULE, DELAYED REL PELLETS;ORAL - EQ 125MG VALPROIC ACID, TABLET, EXTENDED RELEASE;ORAL - EQ 250MG VALPROIC ACID, TABLET, EXTENDED RELEASE;ORAL - EQ 500MG VALPROIC ACID

RELATED EXCIPIENT COMPANIES

12 Evonik, 2 Rochem International Inc, 20 SPI Pharma, 17 DKSH, 1 Pharm-RX Chemical, 11 Boai NKY Pharmaceuticals Ltd, 6 Gangwal Healthcare, 9 Nanjing Well Pharmaceutical, 2 Pfanstiehl, 5 Kirsch Pharma, 4 ACG Worldwide, 8 Actylis, 1 Aeon Procare, 3 Alcedo Pharmachem, 10 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 2 Ashland, 1 Avesta Pharma, 38 BASF, 1 CD Formulation, 2 Clariant, 18 Corel Pharma Chem, 6 DFE Pharma, 3 Doshion Polyscience, 1 Esteem Industries, 2 Finar, 13 Gangwal Chemicals, 1 Huzhou Sunflower Pharmaceutical, 14 Ideal Cures, 5 Ingredion Pharma Solutions, 23 Kerry, 3 Keval Exports, 4 Kima Chemical, 6 Lonza Capsugel, 18 Microlex e.U, 1 Nanjing Bold Chemical, 2 Nitika Pharmaceutical Specialities, 2 Nomisma Healthcare, 5 Novo Excipients, 4 Pharmatrans-Sanaq, 7 Pluviaendo, 4 Prachin Chemical, 1 Qianhao Chemical (Hebei) Co., Ltd, 2 Qualicaps, 27 Roquette, 14 Seppic, 8 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shanghai Welltone Material Technology Co., Ltd, 1 Shijiazhuang Huaxu Pharmaceutical, 11 Sigachi Industries, 4 Silverline Chemicals, 3 The Dow Chemical Company, 2 Ulanqab Kema New Material, 3 Valens Pharmachem, 4 Vasa Pharmachem, 2 Vertellus

EXCIPIENTS BY APPLICATIONS

93 Fillers, Diluents & Binders, 84 Coating Systems & Additives, 46 Disintegrants & Superdisintegrants, 46 Controlled & Modified Release, 44 Direct Compression, 44 Thickeners and Stabilizers, 43 Solubilizers, 38 Granulation, 37 Taste Masking, 30 Film Formers & Plasticizers, 27 Topical, 23 Parenteral, 22 Lubricants & Glidants, 20 Chewable & Orodispersible Aids, 15 Co-Processed Excipients, 14 Rheology Modifiers, 12 Emulsifying Agents, 9 Empty Capsules, 9 API Stability Enhancers, 7 Surfactant & Foaming Agents, 5 Coloring Agents, 4 Vegetarian Capsules

DIGITAL CONTENT

63 News #PharmaBuzz

63 News #PharmaBuzz

GLOBAL SALES INFORMATION

43 US Medicaid Prescriptions, 80 Regulatory FDF Prices, 5 Annual Reports

MARKET PLACE

28 APIs, 16 FDF Dossiers

REF. STANDARDS & IMPURITIES

2 EDQM, 17 Others

ANALYTICAL

1 BioAnalytical Methods

1 BioAnalytical Methods

$ Xls

Filters

Xls

USFDA APPLICATION NUMBER - 18082 / DOSAGE - SYRUP;ORAL - 250MG/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

Ingredient Name	Basis of Strength	Strength
Active Ingredient/Active Moiety
VALPROIC ACID(UNII: 614OI1Z5WI) (VALPROIC ACID - UNII:614OI1Z5WI)	VALPROIC ACID	250mg \| 250mg in 5

Inactive Ingredients

Ingredient Name	AbbVie Inc.
CORN OIL(8470G57WFM)
FD&C RED NO. 40(WZB9127XOA)
FD&C YELLOW NO. 6(H77VEI93A8)
FERRIC OXIDE RED(1K09F3G675)
GELATIN, UNSPECIFIED(2G86QN327L)
GLYCERIN(PDC6A3C0OX)
METHYLPARABEN(A2I8C7HI9T)
PROPYLPARABEN(Z8IX2SC1OH)
SORBITOL(506T60A25R)
SUCROSE(C151H8M554)
TITANIUM DIOXIDE(15FIX9V2JP)
VANILLIN(CHI530446X)
WATER(059QF0KO0R)

Drug Product Composition: Divalproex Sodium